|
| 37783649 | PARP inhibitors for prostate cancer. | Semin Oncol | 2024 |
| 36114082 | B7-H3 as a Therapeutic Target in Advanced Prostate Cancer. | Eur Urol | 2023 |
| 37491606 | A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-â¿¿11q splice variant. | Oncogene | 2023 |
| 37751307 | The catalytic subunit of DNA-PK regulates transcription and splicing of AR in advanced prostate cancer. | J Clin Invest | 2023 |
| 37847874 | Poly(ADP-ribose) Polymerase Inhibitor Combinations in First-Line Metastatic Castration-Resistant Prostate Cancer: Increasing Toxicity With Unclear Benefits. | J Clin Oncol | 2023 |
| 37844613 | Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance. | Nature | 2023 |
| 37652207 | Development and Validation of a New BAG-1L-Specific Antibody to Quantify BAG-1L Protein Expression in Advanced Prostate Cancer. | Lab Invest | 2023 |
| 37502956 | NSD2 maintains lineage plasticity and castration-resistance in neuroendocrine prostate cancer. | bioRxiv | 2023 |
| 37537253 | A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer. | Br J Cancer | 2023 |
| 35750582 | Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1. | Eur Urol | 2023 |
| 37460872 | The Akt/mTOR and MNK/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cells. | Nat Cancer | 2023 |
| 37087376 | PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues. | Eur Urol | 2023 |
| 37040594 | External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. | J Clin Oncol | 2023 |
| 37269841 | Health-related quality of life and pain outcomes with [<sup>177</sup>Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial. | Lancet Oncol | 2023 |
| 37003085 | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. | Eur J Cancer | 2023 |
| 37032186 | Reply to Timothée Olivier, Kerrington Powell, Vinay Prasad. Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.022. | Eur Urol | 2023 |
| 36964041 | Erratum to "B7-H3 as a Therapeutic Target in Advanced Prostate Cancer" [Eur Urol 2023;83(3):224-38]. | Eur Urol | 2023 |
| 37355762 | Critical role of antioxidant programs in enzalutamide-resistant prostate cancer. | Oncogene | 2023 |
| 36697317 | Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer. | Clin Genitourin Cancer | 2023 |
| 36806722 | Systematic study of tissue factor expression in solid tumors. | Cancer Rep (Hoboken) | 2023 |
| 36609007 | A Transgender Patient with Prostate Cancer: Lessons Learnt. | Eur Urol | 2023 |
| 36528479 | Corrigendum to "Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study" [Eur Urol 83 (2023) 15-26]. | Eur Urol | 2023 |
| 36494221 | Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. | Eur Urol | 2023 |
| 36725887 | Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth. | Oncogene | 2023 |
| 36043882 | Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound. | Clin Cancer Res | 2023 |
| 36055895 | Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study. | Eur Urol | 2023 |
| 36318705 | Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA. | Clin Cancer Res | 2023 |
| 34167925 | Prostate-specific Membrane Antigen Biology in Lethal Prostate Cancer and its Therapeutic Implications. | Eur Urol Focus | 2022 |
| 35737639 | Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies. | Cancer | 2022 |
| 35677318 | Neutropenia, neutrophilia, and neutrophil-lymphocyte ratio as prognostic markers in patients with metastatic castration-resistant prostate cancer. | Ther Adv Med Oncol | 2022 |
| 35584120 | H3K9 methylation drives resistance to androgen receptor-antagonist therapy in prostate cancer. | Proc Natl Acad Sci U S A | 2022 |
| 35349486 | Targeting radioresistance and replication fork stability in prostate cancer. | JCI Insight | 2022 |
| 35440417 | Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11]. | Eur Urol | 2022 |
| 35643841 | Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER. | Eur J Cancer | 2022 |
| 35397952 | Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study. | Eur Urol | 2022 |
| 35695870 | Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer. | Clin Cancer Res | 2022 |
| 35568679 | Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. | Eur J Cancer | 2022 |
| 35491356 | Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer. | Eur Urol Oncol | 2022 |
| 35717027 | Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors. | J Immunother Cancer | 2022 |
| 35450732 | Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. | Eur Urol | 2022 |
| 35656509 | Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer-Prevalence and Current Clinical Practice. | Front Oncol | 2022 |
| 35552383 | Prostate-Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer. | Clin Cancer Res | 2022 |
| 36273494 | SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance. | Cancer Res | 2022 |
| 35984704 | A Phase I Trial of CT900, a Novel α-Folate Receptor-Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer. | Clin Cancer Res | 2022 |
| 36124924 | Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses. | Oncologist | 2022 |
| 35157830 | Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial. | Lancet Oncol | 2022 |
| 35317841 | A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer. | Mol Cancer | 2022 |
| 35247924 | A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors. | Clin Cancer Res | 2022 |
| 35092476 | Multiparametric bone MRI can improve CT-guided bone biopsy target selection in cancer patients and increase diagnostic yield and feasibility of next-generation tumour sequencing. | Eur Radiol | 2022 |
| 35091440 | Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib). | Clin Cancer Res | 2022 |